Actinium Pharmaceuticals, Inc. (delaware) · AMEX:ATNM
Actinium Pharmaceuticals, Inc. (delaware) — Actinium Pharmaceuticals — 4th Annual Targeted Radiotherapeutics Summit 2025
24 slides from Actinium Pharmaceuticals, Inc. (delaware)'s conference presentation, Jul 30, 2025
Slide 1: Building a Transformative Ac-225 Portfolio for Next-Generation Precision Oncology
Building a Transformative Ac-225 Portfolio for Next-Generation Precision Oncology Adeela Kamal, Ph.D. Executive Vice President, Head of Research & Development 4th Annual Targeted Radiotherapeutics Summit July 30th, 2025, San Diego
Slide 2: Disclaimer and Safe Harbor
Disclaimer and Safe Harbor The information presented herein contains express and implied forward-looking statements regarding the current intentions, expectations, estimates, opinions and beliefs of Actinium Pharmaceuticals, Inc. (“Actinium”) that are not historical facts. These forward-looking stat
Slide 3: Today's Presentation
Today’s Presentation • Introduction to Actinium Pharmaceuticals Irreversible Double-stranded DNA Breaks • Bridging preclinical to clinical: translational studies by Powerful Alpha-Emitters Ac-225 to optimize efficacy and patient selection 1. Actimab-A for mutation agnostic AML 2. ATNM-400 for therap
Slide 4: Introduction to Actinium
Introduction to Actinium February 18, 2022 Developing first-in-class targeted radiotherapies for indications with high unmet needs to improve patient access and outcomes ATNM: NYSE AMERICAN
Slide 5: Innovation Focused R&D Yields Differentiated, High-Value Programs
Innovation Focused R&D Yields Differentiated, High-Value Programs Robust Experience Across Multiple Validated Cancer Broad Areas of Focus Leveraging Significant Targets & Isotopes Clinical Development Experience Hematology Targeted Conditioning CD33 CD45 CD38 ICI Undisclosed AML, MDS Leukemia, Lymph
Slide 6: Robust Pipeline for Hematology, Solid Tumors and Conditioning
Robust Pipeline for Hematology, Solid Tumors and Conditioning
Slide 7: Heme: Actimab-A for AML
Heme: Actimab-A for AML February 18, 2022 Clinical Therapeutics Program Investigating Combination Approaches ATNM: NYSE AMERICAN
Slide 8: Actimab-A Program: Bolstered by Strong Clinical Data in AML
Actimab-A Program: Bolstered by Strong Clinical Data in AML Backbone therapy potential with mutation agnostic Clinical experience supports late-stage trials and broad mechanism of action and synergistic potential development plan in partnership with NCI CRADA • Actimab-A links the Ac-225 alpha emitt
Slide 9: Enhanced Cytotoxicity: Actimab-A and SoC Combinations in Mutant AML
Enhanced Cytotoxicity: Actimab-A and SoC Combinations in Mutant AML Potent Cytotoxicity with Menin Inhibitors Potent Cytotoxicity with FLT3 Inhibitors or that Target AML Mutations 5-Azacytidine that Target AML Mutations FLT3 mutation KMT2A mutation FLT3 Inhibitor Menin Inhibitors Combination Combina
Slide 10: Combination of Actimab-A with Menin or FLT3 Inhibitors Potentiates In Vivo AML Cell Death
Combination of Actimab-A with Menin or FLT3 Inhibitors Potentiates In Vivo AML Cell Death Anti-AML Efficacy was Significantly Potentiated by SoC Combination in Mice bearing AML Mutant Xenografts KMT2A mutation FLT3 mutation NPM1 mutation Menin Inhibitor Menin Inhibitor FLT3 Inhibitor Combination Com
Slide 11: Combination of Actimab-A with Azacitidine Potentiates In Vivo AML Cell Death
Combination of Actimab-A with Azacitidine Potentiates In Vivo AML Cell Death Actimab-A is Efficacious as Monotherapy Actimab-A is Efficacious as Mono and in and in Combination with 5-Aza in s.c. model Combo with 5-Aza in disseminated model TP53 mutation TP53 mutation HL60: Tumor Volume 2000 Mean Tum
Slide 12: Actimab-A Mechanism of Action: DNA Stress and Damage Signaling
Actimab-A Mechanism of Action: DNA Stress and Damage Signaling Actimab-A Induces pH2AX and p21 in Actimab-A MOA and Effects of Combining with Various WT TP53 but not mutant TP53 AML Cells Inhibitors to Address AML Mutations 12
Slide 13: Actimab-A Summary
Actimab-A Summary • Broad Anti-Leukemic Activity: Effective across AML cell lines, regardless of high-risk mutations (FLT3, NPM1, TP53, KMT2A rearrangements) • Enhanced Efficacy: Improves disease control and durability of response in high-risk AML when used with standard-of-care therapies • Clinical
Slide 14: Solid Tumors: ATNM-400 for Prostate Cancer
Solid Tumors: ATNM-400 for Prostate Cancer February 18, 2022 ATNM-400 – First-in-class, non-PSMA Ac-225 targeted radiotherapy for prostate cancer ATNM: NYSE AMERICAN
Slide 15: ATNM-400: Next-Generation, Non-PSMA Prostate Cancer Radiotherapy
ATNM-400: Next-Generation, Non-PSMA Prostate Cancer Radiotherapy High Unmet Medical Need in Prostate Cancer for Patients Novel, First-in-Class Ac-225 Based Radiotherapy Progressing after Pluvicto Treatment • Over 300,000 patients will be diagnosed with prostate cancer in the U.S. in 2025 and approxi
Slide 16: ATNM-400 Binds, Internalizes and Causes Cytotoxicity in Human Prostate Cancer Cells
ATNM-400 Binds, Internalizes and Causes Cytotoxicity in Human Prostate Cancer Cells ATNM-400 Binds Recombinant Target ATNM-400 Internalizes and Causes Dose- Protein and Target-Positive PCa Cells Dependent Cytotoxicity in PCa Cells ELISA Radioligand Internalization 1.0 IgG 25 ATNM400 0.8 % Standard A
Slide 17: ATNM-400 Exhibits Tumor Uptake and Clearance from Normal Organs
ATNM-400 Exhibits Tumor Uptake and Clearance from Normal Organs Sustained Tumor Uptake and Rapid Clearance from PET Imaging: Specifically Accumulates in Normal Organs in Prostate Cancer In Vivo Model Prostate Cancer Tumor-bearing Animals tumor [89Zr]-mAb [89Zr]-mAb + Cold mAb 17
Slide 18: ATNM-400 Has Potent Efficacy in Preclinical Model of Prostate Cancer
ATNM-400 Has Potent Efficacy in Preclinical Model of Prostate Cancer ATNM-400 causes Dose-Dependent Efficacy and ATNM-400 Significantly Inhibits Tumor Cell Improved Overall Survival in PCa In Vivo Model Proliferation in PCa In Vivo Model Vehicle (PBS) ATNM-400 (40 μCi/kg) % of Ki67 Positive 60 ✱✱ Ce
Slide 19: ATNM-400 is Highly Efficacious and Durable after Pluvicto Resistance in Prostate Cancer Models
ATNM-400 is Highly Efficacious and Durable after Pluvicto Resistance in Prostate Cancer Models ATNM-400 Shows Significantly Higher and ATNM-400 Demonstrates Potent Efficacy and Sustained Tumor Durable Efficacy than Pluvicto in PCa Growth Inhibition After Pluvicto Stops Working 2500 177Lu-PSMA-617 (4
Slide 20: ATNM-400 is More Efficacious than 177Lu-PSMA-617 or 225Ac-PSMA-617
ATNM-400 is More Efficacious than 177Lu-PSMA-617 or 225Ac-PSMA-617 In Vitro: ATNM-400 is More Cytotoxic than In Vivo: ATNM-400 is More Efficacious than 225Ac-PSMA-617 or 177Lu-PSMA-617 in PCa 225Ac-PSMA-617 or 177Lu-PSMA-617 in PCa 22Rv1 Cytotoxicity 2500 Tumor Volume +/-SE (mm3) Vehicle Cold ATNM40
Slide 21: ATNM-400 Exhibits Superior and Durable Efficacy versus Enzalutamide
ATNM-400 Exhibits Superior and Durable Efficacy versus Enzalutamide In Vitro: ATNM-400 is Cytotoxic in Enzalutamide In Vivo: ATNM-400 has Durable Efficacy in Enzalutamide Resistant PCa Cells and has Combination Activity Resistant PCa Model and has Combination Activity Combination 2500 Vehicle Tumor
Slide 22: ATNM-400 Summary
ATNM-400 Summary • Superior Efficacy: Demonstrated robust and durable anti-tumor activity in preclinical prostate cancer models, including: − Enzalutamide-resistant tumors − PSMA-targeted radiotherapy-resistant models (¹⁷⁷Lu-PSMA-617 and ²²⁵Ac-PSMA-617) • Novel Mechanism: Targets a disease-driving p
Slide 23: 2025: Revamped Strategy, Revitalized Programs To Drive Value Creation
2025: Revamped Strategy, Revitalized Programs To Drive Value Creation R&D and Actimab-A Iomab-ACT Capabilities Market expansion with initiation of Commercial CAR-T initiated at UTSW, ATNM-400 is a first-in-class, non- frontline AML trial under NCI CRADA data expected in 2H:2025 PSMA targeting
Slide 24: Thank you
Thank you February 18, 2022 Actinium Pharmaceuticals, Inc. ATNM:NYSE AMEX ATNM: NYSE AMERICAN
Actinium Pharmaceuticals — 4th Annual Targeted Radiotherapeutics Summit 2025 on 6ix